Clinical Trial

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-10.
Status change: Not Yet Recruiting → Recruiting 2025-07-15
Trial Details
NCT Number NCT06826313
Lead Sponsor Guangzhou Virotech Pharmaceutical Co., Ltd.
Collaborators: Third Affiliated Hospital, Sun Yat-Sen University
Conditions Solid Tumors
Enrollment 12 participants
Start Date 2025-03-19
Primary Completion 2025-12-30 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-18